Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes
Author:
Affiliation:
1. Medical Clinic III; University of Cologne; Cologne Germany
2. Takeda Development Centre; London UK
3. Takeda Development Center Americas, Inc.; Deerfield IL USA
Funder
Takeda Pharmaceutical Company
Publisher
Wiley
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12608/fullpdf
Reference33 articles.
1. The prospective pioglitazone clinical trial in macrovascular events (PROactive): Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients;Charbonnel;Diabetes Care,2004
2. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial;Dormandy;Lancet,2005
3. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction. Results from the PROactive (PROactive 05) Study;Erdmann;J Am Coll Cardiol,2007
4. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04);Wilcox;Stroke,2007
5. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive;Dormandy;Drug Saf,2009
Cited by 72 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Effect of pioglitazone on proteinuria and cardiovascular events in patients with diabetic nephropathy;Journal of Renal Injury Prevention;2023-08-05
2. In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome;Diabetes, Obesity and Metabolism;2023-08-03
3. Microglial Metabolic Reprogramming: Emerging Insights and Therapeutic Strategies in Neurodegenerative Diseases;Cellular and Molecular Neurobiology;2023-06-21
4. Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis;Diabetologia;2023-05-12
5. Diabetic vascular diseases: molecular mechanisms and therapeutic strategies;Signal Transduction and Targeted Therapy;2023-04-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3